Dr. Lal Pathlabs Limited — Investor Presentation 2023

Jul 27, 2023

==> picture [612 x 65] intentionally omitted <==

July 27, 2023

National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524

Sub: Earnings Presentation on Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2023

Dear Sir/ Madam,

Please find attached a copy of Company's Q1 FY24 Earnings Presentation, which the Company proposes to share with Analysts/ Investors with respect to its Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2023, as approved by the Board of Directors in their meeting held on July 27, 2023.

We request you to please take the same on record.

Thanking You, Yours Faithfully,

For Dr. Lal PathLabs Limited

VINAY

GUJRAL

Digitally signed by VINAY GUJRAL DN: c=IN, st=Haryana, 2.5.4.20=0fa538e55ae7b0266a2316103152d8776702b6422f0d 8a36edadf26c85c60a16, postalCode=121004, street=Flat No 502 Ambience CGHS Ltd GH-4 Sector-2 Ballabgarh, pseudonym=ef8f0b52b0d8c14f4dad79c263665819, serialNumber=3086abc082bae5dcf46bd0def545ce423776354 5c86d24c0cc0c5382400562c0, o=Personal, cn=VINAY GUJRAL Date: 2023.07.27 14:54:13 +05'30'

Vinay Gujral

Company Secretary & Compliance Officer

Encl.: As above

==> picture [593 x 67] intentionally omitted <==

==> picture [228 x 60] intentionally omitted <==

Dr. Lal PathLabs Limited (DLPL) Q1 FY24 Results Presentation July 27, 2023

==> picture [43 x 43] intentionally omitted <==

==> picture [368 x 224] intentionally omitted <==

==> picture [368 x 223] intentionally omitted <==

Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward-looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

==> picture [88 x 28] intentionally omitted <==

2

Table of Contents

==> picture [753 x 357] intentionally omitted <==

----- Start of picture text -----

Dr Lal PathLabs – At a Glance 4
Overview of Dr Lal PathLabs 5
Key Performance Highlights 6
Financials 7
Operating Highlights 9
Management Commentary 10
Corporate Overview 11
Shareholding 27
Contact Us 28
DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operations remain subject to undetermined contingencies
Classification: and risks. Dr Lal PathLabs Limited would not be liable for any action Restricted undertaken based on such ‘forward-looking’ statements and does not commit to revising/updating 3
thempublicly.
----- End of picture text -----

Dr Lal PathLabs – At a Glance

==> picture [771 x 366] intentionally omitted <==

----- Start of picture text -----

15% 13% 120%
India’s Leading 70+ years of
& Trusted experience in 3 Year Revenue 3-Year Equity Dividend
Diagnostics the field of CAGR Normalised for FY 22-23
Company diagnostics EBITDA CAGR
Largest diagnostics
chain in the country 24% 277 5,102
with PAN India
presence and consistent ROCE Labs; Geographically Patient Service
track record of quality Excl. Cash & spread-out network Centers (PSC’s)
Investments
and growth
36 NABL
111 Mn patients
accredited Labs; Rs. 877 Cr. Rs. 146 Cr.
serviced in last 5,191
2 CAP accredited
5 years Cash & Investments as on OD/TL as on
Labs Pathology &
Radiology tests; 30 [th] June, 2023 30 [th] June, 2023
Comprehensive Test
menu
As on March 31, 2023
Largest on the basis of revenue and presence 4
Note: Figures includes Suburban Diagnostics w.e.f. 12 [th] November, 2021
----- End of picture text -----

Overview of Dr Lal PathLabs

==> picture [67 x 311] intentionally omitted <==

Established brand

Established consumer healthcare brand in diagnostic services

Pan-India 277 clinical labs (including National Reference Lab at Delhi and integrated Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs) coverage*

Varied Catalogue of 481 test panels, 2,763 pathology tests and 1,947 Offerings radiology and cardiology tests Unique and Scalable model integrated through centralised IT platform allows successful for network expansion operating model

Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

• Includes 40 Labs, 207 PSC’s and 1008 PUP’s of Suburban Diagnostics

As on March 31, 2023

==> picture [88 x 28] intentionally omitted <==

5

Q1 FY24 – Key Performance Highlights

==> picture [744 x 356] intentionally omitted <==

----- Start of picture text -----

INR 528 Cr
+9.7%
Non-Covid Revenue
INR 154 Cr 28.4% INR 541 Cr
+7.6%
Normalised EBITDA Margin Total Revenue
INR 84 Cr 15.4% INR 112 Cr 22%
PAT Margin Contr.
Swasthfit Revenue
Normalised EBITDA excl. RSU and CSR cost
6
----- End of picture text -----

• Normalised EBITDA excl. RSU and CSR cost

Financials

==> picture [604 x 318] intentionally omitted <==

----- Start of picture text -----

Particulars (Rs. Cr.) Q1 FY24 Q1 FY23 Gr % FY'23
Revenue 541 503 7.6% 2,017
Operating Expenditure 387 377 1,489
Normalised EBITDA 154 125 22.7% 528
Normalised Margins 28.4% 25.0% 26.2%
RSU & CSR cost 8 8 38
EBITDA 146 118 24.4% 490
Margins 27.0% 23.4% 24.3%
Other Income 14 8 42
Depreciation 35 36 150
EBIT 126 90 39.6% 381
Margins 23.2% 17.9% 18.9%
Finance Cost 8 8 38
PBT 117 81 44.3% 344
Margins 21.7% 16.2% 17.0%
PAT 84 58 43.6% 241
Margins 15.4% 11.6% 12.0%
EPS (Basic) 9.9 7.0 28.8
----- End of picture text -----

Financial results of the Company are best monitored on a year-to-date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

==> picture [88 x 28] intentionally omitted <==

7

Financial Highlights – Consolidated

All figures in Rs. Crore

==> picture [729 x 239] intentionally omitted <==

----- Start of picture text -----

Revenue Normalised EBITDA PBT PAT
Non Covid Covid
8%
541 154
503
13
21
125
117
10%
Margin 84
81
482 528 12%
Margin Margin Margin Margin 58 Margin
25% 28% 16% 22% 15%
Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24
----- End of picture text -----*

• Normalised EBITDA excl. RSU & CSR

Financial results of the Company are best monitored on a year-to-date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

==> picture [88 x 28] intentionally omitted <==

8

Operating Highlights

==> picture [758 x 316] intentionally omitted <==

----- Start of picture text -----

No. of Clinical Laboratories No. of PSCs No. of PUPs
+61 +2,007 +3,943
4,731 5,102 10,599 10,938
216 231 277 277 3,705 9,247
3,095 6,995
FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23
No. of Patients (Mn) No. of Samples (Mn)
+39%
+52%
27.3 26.9 72.3
19.4 20.3 66.0
47.7 49.7
6.9 19.3
FY20 FY21 FY22 FY23 Q1 FY24
FY20 FY21 FY22 FY23 Q1 FY24
----- End of picture text -----

Note: Includes 40 Labs, 207 PSC’s and 1008 PUP’s of Suburban Diagnostics

==> picture [88 x 28] intentionally omitted <==

9

Management Commentary

Commenting on the performance, (Hony) Brig. Dr. Arvind Lal, Executive Chairman said:

“As a frontrunner in organized diagnostics, we believe we have consistently met patient expectations on service parameters. We are focused single mindedly on driving volume growth and our methodical approach to network expansion will take lead. Given our strong operating model and brand affinity in both B2C and B2B segments, I see the Company gain share from the unorganized space.

There is synergy to be leveraged across both our brands and this will form the basis for business performance in the Western India as we fully tap the potential of our new RRL at Vidyavihar. We are constantly focused on expanding our presence to reach a larger number of customers, especially in the tier 3 and 4 cities.

Diagnostics industry in India remains dynamic, offering ample opportunities for future expansion. The industry is shifting gears from being an unorganized market largely to one that is organized. This encouraging shift is expected to gain traction in the coming period, helping large national players like us to further cement our leadership position in the country.”

==> picture [129 x 95] intentionally omitted <==

(Hony) Brig. Dr. Arvind Lal, Executive Chairman

Commenting on the performance, Dr. Om Manchanda, Managing Director said:

“Over the next few years, we expect a rapid shift of market share from unorganized to organized, driven by changing industry dynamics and certain intrinsic benefits available to large organised players. Our omnichannel focus is further accelerating this shift as we seamlessly transport samples and deliver reports conveniently with best-in-class patient experience.

Our digital investments have grown manifold in the past few years largely directed towards enhancing the IT infrastructure, including the implementation of advanced technologies to drive higher volumes. These efforts aim to elevate the patient experience and provide tailored solutions to meet customized needs.

We continue to focus on highly specialized segments of pathology testing. Our approach has been to focus on these segments through Centre of Excellence (CoE). Dr. Lal PathLabs has strengthened its reputation as a reliable and patient-centric company, and we are committed to leaving our imprint and continuing the growth trajectory.”

Dr. Om Manchanda, Managing Director

Commenting on the performance, Mr. Bharath Uppiliappan, Chief Executive Officer said:

“In Q1 FY24 we served 6.9 million patients generating a revenue of Rs. 541 crore with a growth of 8%, Non Covid growth of 10%. This was largely led by Sample growth of 6% and higher realization. In this quarter we launched our new marketing campaign “Bharat ka Vishwas” with quantifiable reasons to believe why millions of patients and doctors trust Dr Lal Pathlabs. This combined with our digital led initiatives - CHIPs and Recommendation engine supported with on ground activation programs are driving growth in our stronghold markets of North & East. DNCR recorded a strong growth rate.

Swasthfit registered highest ever quarterly revenue of Rs 112 Cr with a contribution of 22% to topline. We are creating variants of common tests like Lipid profile & making it medically more relevant sub segments of patients like diabetics & heart related ailments. Our strategic expansion in Tier 3 & 4 cities of the country continues as per plan. In addition to the labs in Siwan, Sultanpur & Murshidabad in Q4 FY23, we have commenced operations at 4 of our greenfield labs in Jind in Haryana, Una in Himachal Pradesh & Tamluk & Hooghly in West Bengal.

We believe we have the right set of building blocks coupled with PAN India presence and the digital infrastructure that will help us to deliver industry leading growth rates for a long period of time.”

Mr. Bharath Uppiliappan, Chief Executive Officer 10

==> picture [88 x 28] intentionally omitted <==

----- Start of picture text -----

10
----- End of picture text -----

==> picture [228 x 60] intentionally omitted <==

==> picture [60 x 60] intentionally omitted <==

Corporate Overview

==> picture [211 x 187] intentionally omitted <==

==> picture [43 x 43] intentionally omitted <==

==> picture [368 x 224] intentionally omitted <==

==> picture [368 x 223] intentionally omitted <==

Vision, Mission & Values

==> picture [677 x 313] intentionally omitted <==

----- Start of picture text -----

Be the most trusted
Customer First
healthcare partner,
enabling healthier
VISION
lives Ethics &
Integrity
Quality
To be an undisputed market
leader by providing accessible, VALUES
affordable, timely and quality
healthcare, diagnostics, applying MISSION Accountability
insights and cutting-edge
technology to create value for
Empathy &
all stakeholders
Compassion
----- End of picture text -----

Classification: Restricted

==> picture [88 x 28] intentionally omitted <==

12

Vibrant Outlook

==> picture [671 x 261] intentionally omitted <==

----- Start of picture text -----

Evaluate best fit inorganic Strongly develop Rest of India
opportunities in South, and leverage geographies, through Regional
expertise of recently acquired Reference Labs and cluster city
Suburban brand in West approach for attractive markets
Target to grow
ahead of the
industry
Deeper Penetration within the
Higher contribution from
North, East & Central Indian
bundling of tests – ‘Swasthfit’
markets
----- End of picture text -----

==> picture [88 x 28] intentionally omitted <==

13

Classification: Restricted

DLPL Strategy for future growth

Significantly leverage the strong digital infrastructure

• Deployed AI, data analytics, machine learning tools to elevate the patient experience & offer customized solutions

• Dedicated digital team in place to amplify the volume trajectory

Enhance high-end test portfolio of super-specialty & bundled test

• Created specialty verticals like Genevolve to focus on genomics, L-CoRD to focus on reproductive diagnostics, and L-ACE to focus on auto-immune disorders.

• ‘Swasthfit’ remains at the core, to offer comprehensive bundled solutions to patients

Maintain leadership position in the existing core markets

• Leverage strong brand equity in core markets of North India including Delhi NCR

• Offer value to patients by upselling opportunities

==> picture [393 x 94] intentionally omitted <==

Drive higher volumes in high-potential markets of Western & Southern India

• Follow cluster city approach to steer growth in key pockets

• Enhance presence in Maharashtra especially Mumbai through Suburban Diagnostics

• Launched Reference labs in Bengaluru & Mumbai

==> picture [88 x 28] intentionally omitted <==

14

Classification: Restricted

Leveraging digital infrastructure to make life easier for patient

New Website Launch

Wallet

• New age user intuitive website.

• Responsive , mobile friendly web designs.

• SEO friendly for improved customer reach

==> picture [269 x 206] intentionally omitted <==

• Strategic placement of Buttons and Web forms to generate more leads and better order conversion rates from website

Reco.ai

• LPL’s own AI based Recommendation Engine

• Recommends Patient relevant tests as per his current health condition, past report trends, demographic details, etc.

Logistics App

• Machine Learning based FE Route Generation

• Machine Learning based Tube Scanning Bag creation process.

• Secure QR Code based handshake for every process.

• Geo-fencing and Precious sample recognition Intra and Intercity sample movement.

• Senior Citizen Wallet: Wallet points on every booking for Senior Citizen Patients.

• Phlebo Wallet: Wallet points on enhanced superior services to customers.

One Registration

• One unified platform for all POS registrations

• • Error Proofing

Chatbot 2.0

• New version of Chatbot.

• Book an appointment functionality. ETR and Report visibility of customer orders. Recommendation of Preventive Health Checkups

Classification: Restricted

==> picture [88 x 28] intentionally omitted <==

15

Summary highlights – Technical Lab Operations

==> picture [42 x 43] intentionally omitted <==

==> picture [38 x 39] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

LACE and the centre of excellence in Reproductive medicine – LCORD

Only lab in India to introduce the Donor derived cell free DNA (LIQUID BIOPSY) technique for monitoring in cardiac, lung and renal transplant patients.

Relaunched the Lipid panels incorporating the latest guidelines and the SCVD risk profiling for patients

First lab to introduce the ONCOPRO TSO500 Comprehensive Genomic Profiling- 500 genes panel

==> picture [38 x 39] intentionally omitted <==

==> picture [39 x 38] intentionally omitted <==

First lab in India to use AI as an adjunct reporting for prostate cancer and breast cancer reporting – enhancing the accuracy of pertinent parameters for reporting which affect the therapy guidelines for patients (Gleason grading and perineural invasion)

New Research paper published Launched COE in Only private lab to have two entitled “Emergence of Autoimmunity – electron microscopes – TEM Multidrug Resistant Unparalled test menu in (Transmission Electron Enterococcus Species Isolated autoimmune diseases in Microscopy ) for clinical from Clinical Samples in India diagnostics. North India” in international journal Global Journal of Microbiology Research(GJMR).

==> picture [693 x 41] intentionally omitted <==

Classification: Restricted

==> picture [88 x 28] intentionally omitted <==

16

Savings of >1.3 million aliquots and >5210 tons of plastic waste in our lab – a strong commitment to sustainability

Dr. Lal Pathlabs’ leadership vision focuses on continuous improvement while maintaining best-in-class patient services. Furthermore, we are strongly committed to optimizing our laboratory’s environmental footprint.

We reduced the need for aliquots by 93% by replacing our previous system configuration[1,2] with new, innovative automation, analyzers, and IT solutions. Reduced use of plastic for aliquots optimizes waste management and significantly reduces CO[2] emissions.

==> picture [758 x 223] intentionally omitted <==

----- Start of picture text -----

Equivalent to carbon
>1.3 millions >INR 435 millions sequestered by
3231 tree
aliquots eliminated saved in aliquot seedlings
per year [2] creation cost [2,5]
>21,571 tons grown for 1 year [4]
>5210 tons
of CO
2 emissions
of plastic waste eliminated [3] eliminated every year [4]
CO2
Saving energy
Protecting Reducing the Combating climate Supporting return
required for aliquot
resources carbon footprint change on investment
creation
----- End of picture text -----

1. Siemens Healthineers automation and IT solution vs. the previous system configuration from Roche Diagnostics, Abbott Diagnostics, and Beckman Coulter Diagnostics.

2. Case study: Dr. Lal Pathlabs harnesses the power of digitalization. Published by Siemens Healthcare Diagnostics Inc. · Order No. 30-22-DX-1342-76 · 08-2022 · © Siemens Healthcare Diagnostics Inc., 20222.

3. ZWE_Policy-briefing_The-impact-of-Waste-to-Energy-incineration-on-Climate.pdf

Classification: Restricted

1. Theoretical worldwide average using the epa.gov/energy/greenhouse-gases-equivalencies-calculator

2. Expected financial savings for the contract duration, depending on test mix and market pricing during this time period.

==> picture [12 x 8] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

==> picture [88 x 28] intentionally omitted <==

Key ESG Initiatives

==> picture [734 x 314] intentionally omitted <==

----- Start of picture text -----

Use of Solar E-billing and e-
Use of Electric
Panels for Power; payment receipt
bikes for sample
addition of 50 KW to reduce paper
collection
solar plant at NRL usage
Data centre Water saving
virtualization to through treatment
prevent heat and & reuse of
CO2 emission wastewater
Use of Descaling of DG 31348 hours of
biodegradable Sets radiator to training for
bags for sample improve the employee
collection smoke quality development
----- End of picture text -----

Classification: Restricted

==> picture [12 x 8] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

==> picture [88 x 28] intentionally omitted <==

Cyber Security Capability

==> picture [568 x 40] intentionally omitted <==

----- Start of picture text -----

||||
|---|---|---|
|Data Loss|•|State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information|
|•|Data classification platform for information labeling and handling according to severity of data|
|Prevention|
|•|Rights management system to enable persistent data-centric protection|

----- End of picture text -----

==> picture [35 x 34] intentionally omitted <==

==> picture [35 x 35] intentionally omitted <==

• Deployed next generation cyber technologies such as CASB (Cloud Access Security Broker), EDR (Endpoint Detection & Extended Response), ATP (Advance Threat Protection), File Sandboxing, Email Zero-Day Protection, Risk-Based Conditional access to Detection and prevent the new-age cyberattacks Response

• Software • Vulnerability Assessment & Penetration Testing of IT apps and systems including cloud infra • Periodic secure code and configuration reviews of mission-critical systems

• Security • Security Security operations center to monitor cyber threats 24x7

• • Cyber Crisis Management Plan - Readiness, Response & Recovery to achieve the cyber resiliency Operations Center

• Threat • Threat intel platform to monitor the surface, deep and dark web for credential disclosures, data leaks, frauds, scams, etc

• Intelligence • Proactive detection and mitigation of vulnerabilities of publically exposed systems

==> picture [24 x 24] intentionally omitted <==

Classification: Restricted

==> picture [88 x 28] intentionally omitted <==

19

Genevolve: Genetic Testing Division

==> picture [62 x 237] intentionally omitted <==

==> picture [131 x 43] intentionally omitted <==

==> picture [122 x 275] intentionally omitted <==

----- Start of picture text -----

Onco Genomics
Neuro
Genomics
Reproductive
Genomics
Rare Disease
----- End of picture text -----

==> picture [194 x 251] intentionally omitted <==

----- Start of picture text -----

Successful completion of 3 years of
Launch
Wide Test offering with 160+ New Tests
Wellness Genomics & Pharmacogenomics
are upcoming segment
Direct reach of 3000+ Doctors
Dedicated Business Development team
for Genetic Tests
State of art technologies In-House at 4
Reference Labs
----- End of picture text -----

==> picture [88 x 28] intentionally omitted <==

20

Classification: Restricted

Highest Quality Standards in the Industry

Best in the Industry CAP Proficiency Testing Score at 99.5% for National Reference Lab

Consistently high EQAS Performance Testing Score at 98.5% for Satellite Labs

CAP accreditation 2 labs, NABL accreditation 36 Labs

100+ Quality Digitally enabled Real time quality Risk based improvement solutions control quality assurance meetings on a daily implemented for monitoring framework basis with the quality audits network partners and trainings 21

As on March 31, 2023

Classification: Restricted

Quality Control

==> picture [286 x 321] intentionally omitted <==

Laboratory excellence

Test Recommendation engine NABL 133 implementation Risk Based Internal Audits LPL proficiency testing program launch Analytical Quality Scoring & monitoring of Labs ESG Data Gathering process implementation

Classification: Restricted

Capability building

D L Shah Gold Award for LPL Project ‘Improving Laboratory Performance by developing an in-house automated process to monitor Quality control’ PROJECT NEEV- self learning initiative for phlebotomists Quality education programs-- HUNAR for technicians and EDGE for Doctors

==> picture [88 x 28] intentionally omitted <==

22

Enhanced Customer Experience in Home Collection

==> picture [286 x 277] intentionally omitted <==

Real time 30 minutes slot visibility & booking for the patient Auto Routing engine to dynamically allocate the booking to nearest available phlebotomist Real time phlebo visibility to the patient

D2C- Automated lead management Digital ID card & ratings of Phlebo to the patient Variable model which grows with business volume

==> picture [88 x 28] intentionally omitted <==

23

Experienced Management team

==> picture [104 x 103] intentionally omitted <==

==> picture [104 x 103] intentionally omitted <==

(Hony.) Brig. Dr. ArvindLal Dr. Om Manchanda Executive Chairman Managing Director

Managing Director

==> picture [104 x 103] intentionally omitted <==

Dr. Vandana Lal

Whole-time Director

==> picture [104 x 103] intentionally omitted <==

==> picture [104 x 103] intentionally omitted <==

Bharath Uppiliappan Ved Prakash Goel Chief Executive Officer Group Chief Financial Officer

==> picture [103 x 103] intentionally omitted <==

==> picture [103 x 103] intentionally omitted <==

Shankha Banerjee

Shankha Banerjee Munender Soperna Chief Executive Officer Chief Information Officer (Group Cos)

==> picture [103 x 103] intentionally omitted <==

Jai Prakash Meena Chief Operating Officer

==> picture [103 x 103] intentionally omitted <==

Manoj Garg Group Chief Human Resources Officer

==> picture [88 x 28] intentionally omitted <==

24

Key Awards & Recognition

==> picture [412 x 151] intentionally omitted <==

----- Start of picture text -----

Top 100 Global Most Loved Gold Award
Workplace Business Standard Star
QCI – D. L. Shah Quality Awards -
SME of the year 2022
2023 2022
----- End of picture text -----

==> picture [68 x 79] intentionally omitted <==

==> picture [99 x 53] intentionally omitted <==

Best Brands GAPIO Excellence in Healthcare 2022 Diagnostics Award 2022

==> picture [749 x 148] intentionally omitted <==

----- Start of picture text -----

Financial Express CFO of
Diagnostic Chain of the Year – West CSR Award 2022 ICICI Lombard & CNBC TV18 India CFO100 Roll of the year 2022
Awarded by the prestigious Risk Management Awards 2022 – Honour 2022
Healthcare Awards, from The Healthcare
Economic Times in 2022
----- End of picture text -----

==> picture [88 x 28] intentionally omitted <==

25

Key Awards & Recognition

==> picture [759 x 151] intentionally omitted <==

----- Start of picture text -----

Data Quest Technology VC Circle Healthcare Computerworld
Dr. Om Manchanda honoured and EY Entrepreneur of The Year Award 2015 – Excellence in Summit 2013 – Best Honors Laureate
2019 – Life Sciences &
awarded as ‘Healthcare Personality Implementation of Diagnostic Company Program, 2012
Healthcare
of the Year, 2020’ by FICCI Technology
----- End of picture text -----

==> picture [614 x 150] intentionally omitted <==

----- Start of picture text -----

Frost and Sullivan 4th Annual Franchise India
India Healthcare Excellence Excellence Award in
Award, 'Diagnostic Service Hall of Fame Category Franchisor of the Year Padma Shri – (Hony)
Provider Company of the Year 2012' (2011, 2012) (Healthcare) - Franchise Plus Awards 2010 Brig. Dr. Arvind Lal (2009)
----- End of picture text -----

==> picture [88 x 28] intentionally omitted <==

26

Shareholding as of 30 June, 2023

23.7% FPIS, FDI & NRIs 15.4% Others 5.9% Mutual Funds*

==> picture [293 x 281] intentionally omitted <==

55.0% Promoter and Promoter Group

*Mutual Funds includes Alternate Investment Funds as well

27 27

Contact Us

About Dr Lal PathLabs Limited (DLPL)

Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 481 test panels, 2,763 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2023.

As on March 31, 2023, DLPL’s has 277 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs). In FY22 & FY23, DLPL collected and processed approximately 66 million samples and 72 million samples from 27.3 million and 26.9 million patients, respectively.

Additional information on Dr Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388 Website: https://www.lalpathlabs.com

Ved Goel Siddharth Rangnekar / Nishid Solanki Dr Lal PathLabs Limited CDR India For further Tel: +91 124 301 6500 Tel: +91 22 66451209 / 1221 information Fax: +91 124 423 4468 Fax: +91 22 66451213 please contact: E-mail: ved.goel@lalpathlabs.com Email: siddharth@cdr-india.com / nishid@cdr-india.com

==> picture [88 x 28] intentionally omitted <==

28

==> picture [228 x 60] intentionally omitted <==

==> picture [60 x 60] intentionally omitted <==

==> picture [43 x 43] intentionally omitted <==

Thank you

==> picture [173 x 190] intentionally omitted <==

==> picture [211 x 187] intentionally omitted <==

==> picture [368 x 224] intentionally omitted <==

==> picture [368 x 223] intentionally omitted <==